Tty Biopharm Sustainability Profile
Tty Biopharm Corporation, commonly referred to as Tty Biopharm, is a prominent player in the biopharmaceutical industry, headquartered in Taiwan (TW). Founded in 1966, the company has established itself as a leader in the development and manufacturing of innovative pharmaceuticals, particularly in oncology and other therapeutic areas. With a strong presence in both domestic and international markets, Tty Biopharm is renowned for its commitment to quality and research-driven solutions. The company’s core offerings include a diverse range of generic and proprietary medications, distinguished by their efficacy and safety profiles. Notable achievements include strategic partnerships and a robust pipeline of products that cater to unmet medical needs, solidifying Tty Biopharm's position as a trusted name in the biopharmaceutical landscape.
DitchCarbon Score
How does Tty Biopharm's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Tty Biopharm's score of 50 is higher than 67% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Tty Biopharm's reported carbon emissions
In 2024, TTY Biopharm, headquartered in Taiwan (TW), reported total carbon emissions of approximately 12,539,339 kg CO2e. This figure includes 1,910,257.1 kg CO2e from Scope 1 emissions, 8,116,446.8 kg CO2e from Scope 2 emissions, and 2,512,635.2 kg CO2e from Scope 3 emissions. The combined Scope 1 and 2 emissions totalled about 10,026,703.9 kg CO2e. Comparatively, in 2023, the company recorded total emissions of about 12,738,547.2 kg CO2e, with Scope 1 emissions at 1,700,218.1 kg CO2e, Scope 2 emissions at 8,488,804.8 kg CO2e, and Scope 3 emissions at 2,549,524.3 kg CO2e. This indicates a slight reduction in total emissions from 2023 to 2024. TTY Biopharm has not set specific reduction targets or initiatives as part of its climate commitments, and there are no emissions data cascaded from a parent or related organization. The company has disclosed emissions across all three scopes, demonstrating transparency in its reporting practices.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | - | 000,000 | 0,000,000 | 000,000 | 000,000 | 000,000 | 0,000,000.0 | 0,000,000.0 | 0,000,000.0 |
| Scope 2 | - | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000.0 | 0,000,000.0 | 0,000,000.0 |
| Scope 3 | 625,000 | - | - | - | - | - | 0,000,000.0 | 0,000,000.0 | 0,000,000.0 |
How Carbon Intensive is Tty Biopharm's Industry?
How Carbon Intensive is Tty Biopharm's Location?
Tty Biopharm's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Tty Biopharm has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
